Compare Snap Inc (SNAP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs BIO-TECHNE Corp — how do they compare? Snap Inc trades at $5.31 (market cap $9.18B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| SNAP | TECH | |
|---|---|---|
Market Cap | $9.18B | $11.34B |
Sector | Media | Health |
52-Week High | $9.09 | $72.48 |
52-Week Low | $3.93 | $43.31 |
Enterprise Value | $10.75B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $5.43, down 0.73% with a bullish technical signal despite recent legal pressures. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M net income). Analyst consensus is mixed with 38% buy ratings and a $7.02 price target, while recent news highlights leadership changes and ongoing youth-safety lawsuits.
Snap presents a turnaround story with operational improvements but faces significant legal and competitive risks. The stock offers potential upside to analyst targets if execution continues, though persistent losses and regulatory challenges warrant caution for investors seeking stability.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
